Introduction
Advances in genetics and molecular biology research have generated an increased interest in the field of gene therapy among clinical dermatologists. As researchers continue to close the gap between basic research and clinical science, several clinical applications of gene therapy have recently been attempted, and many others appear to be on the horizon. Originally, gene therapy was introduced as a mechanism to replace absent or defective genes in heritable disorders. In fact, many heritable cutaneous disorders have well-characterized genetic defects, making them favorable targets for gene therapy. (See Table 1 for list of genodermatoses with known gene defects). This field of research is currently being studied in detail, with many studies showing promising results both in animal models in vivo and in cell culture in vitro. However, the applications of gene therapy are not limited to the correction of genetic diseases. In fact, gene therapy has evolved to include genetic vaccination, suicide genes for cancer therapy, immunomodulation, and genetic pharmacology, among other applications ( Figure 1 ).
The Gene Gun: Current Applications in Cutaneous Gene Therapy 
Fig. 1. Clinical applications of gene therapy. As indicated, (1) skin can be used as a target for correction of genetic defects in hereditary skin diseases. (2) Accessibility of skin makes it an ideal tissue to administer genetic vaccines. (3) Similarly, DNA encoding immunostimulatory molecules is introduced, causing an augmented immune response. (4) Genetically engineered cells, particularly tumor cells or hyperproliferative cells, can be targeted by a gene which converts a prodrug to a toxic compound causing the "suicide" effect. (5) Expression of pharmacological proteins in the skin can result in introduction of these molecules either systemically into the circulation or locally into the immediate environment.

(1) Gene Therapy for Genetic Diseases
Genetically Engineered Skin
The skin's easy accessibility and visualization makes it an attractive target for gene therapy. 25 The two major delivery strategies currently being tested in cutaneous gene therapy are in vivo and ex vivo delivery (Figure 2) . 39 In vivo delivery involves the introduction of genetic material directly into the skin of the patient. 79 In contrast, ex vivo delivery involves removal of a skin sample from the patient, propagation of skin cells in tissue culture, introduction of genetic material into the cultured cells, and return of an epithelialized skin equivalent back to the patient (Figure 2 ).
Currently, multiple modalities for gene delivery are being developed for both in vivo and ex vivo approaches. The most widely tested viral vectors are those derived from recombinant adenovirus or retrovirus. Newer viral delivery systems, including the adeno-associated virus, herpes simplex virus, and lentivirus offer possible alternative methods. Distinct advantages and disadvantages govern the applicability of each viral system in gene therapy. These restrictions are based upon the size of the insert, characteristics of the target cells (dividing vs. non-dividing), potential for long-term expression, immunogenicity, and the ability for genomic integration (Table 2) . 32 In addition to viral systems, naked DNA can be delivered to the epidermis by gene gun, liposomes, and receptor-mediated endocytosis of DNA/ligand conjugates.
The Gene Gun Approach
Originally, particle-mediated gene transfer was developed by Sanford and colleagues in 1987 to deliver genes to plant cells using gunpowder acceleration. 34, 35 Eventually, helium replaced gunpowder as the particle propellant for most particle-mediated devices. 82 Currently, hand-held instruments have been developed to utilize the ballistic particle-mediated delivery system (the "gene gun" approach) to deliver genes into skin in vivo. Commercially, these devices are available, such as the Helios ® gene gun (Bio-Rad, Hercules, California) ( Figure 3A ). The "gene gun" accelerates DNA-coated gold particles into target cells or tissues ( Figure 3B ). The gold particles are typically approximately 1 mm in diameter. Due to their small size the particles can penetrate through the cell membrane, carrying the bound DNA (typically 0.5-5.0 µg/particle) into the cell. At this point, the DNA disassociates from the gold particle and can be expressed. Since this method is cell receptorindependent, it can successfully deliver genes into different mammalian cell types; however, it is physically limited by the degree of penetration into the tissue. Previous experiments with the gene gun have shown high levels of local transgene expression, 82, 84 epidermal and dermal penetration in mouse skin, 44 and transient expression lasting at least 48 hr. 43 Some of the advantages of the gene gun over other in vivo delivery systems include: (1) freedom from use of complex biological systems (i.e., viruses) and toxic chemicals (i.e., liposomes/ cationic agents/ligands), (2) cell receptor-independent delivery, (3) delivery of different sizes of DNA, including very large ones, (4) lack of extraneous DNA or protein introduced, and (5) possibility for repetitive treatments. 
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Current Applications of the Gene Gun GENE REPLACEMENT
Since particle-mediated DNA delivery typically results in the short-term and inefficient expression of gene products in vivo, this approach has not been extensively investigated as yet as a means of gene replacement. Nevertheless, several studies have shown the successful introduction of reporter genes to a variety of skin and other organs. 10, 44, 82, 84 Furthermore, the introduction of dystrophin cDNA to skeletal muscle by gene gun in a mouse Duchenne muscular dystrophy model has resulted in detectable levels of dystrophin protein by immunocytochemistry for up to sixty days after bombardment. 85, 86 However, in vivo particle-mediated delivery results in a transient transfection, with no genomic integration. Therefore, the retrovirus and other related viruses capable of integrating genes into the host genome have shown more potential for long-term gene replacement in the skin. Long-term expression (>40 weeks) of a reporter gene, β-galactosidase, has been demonstrated in retrovirally transduced human keratinocytes that were grown in cell culture and grafted onto athymic mice. 37 
Genetic Vaccination
Genetic vaccination is an intriguing application of gene gun technology. Within the broad classification of genetic vaccination, the two significant applications are the pathogen vaccines and the cancer vaccines. Immunization is achieved by the introduction of DNA 21 or mRNA 58 into the skin, leading to the expression of the foreign antigen and subsequently the elicitation of an immune reaction. DNA vaccines forego many of the potential safety concerns related to the biological hazards involved in live-attenuated, protein-purified, or killed vaccines. 40 Possible advantages of DNA vaccination over recombinant proteins for immunization include increased purity of antigens, higher effectiveness of immune elicitation, and lower cost. 40 Intramuscular (IM) injection of DNA has been studied extensively for DNA vaccination; however, gene gun vaccination has also been shown to be effective in producing immunity. Cutaneous DNA vaccination takes advantage of the antigen presenting capabilities of Langerhans cells to elicit a T-cell mediated immune reaction. 36, 73 Several studies have suggested that different delivery modalities may affect the vaccine's effectiveness in eliciting either cell-mediated (largely Th1) or humoral immune responses (largely Th2). 54, 69 The injection of plasmid DNA in a saline solution into the skin or muscle results in a largely T helper 1-like (Th1) immune response in mice, while particle-bombardment to the skin results preferentially in a T helper 2-like (Th2) response. This bias may be related to the mode of delivery (DNA uptake vs. direct intracellular penetration) and/or quantity of DNA introduced. Dose-dependent non-specific immune responses can be triggered by plasmid DNA prepared from bacteria due to unmethylated DNA sequences. 63 Lower Th1 responses are observed in particle-mediated immunization since it requires one-hundredth as much plasmid DNA than direct injection. 73 The first evidence of particle-mediated DNA immunization occurred when Johnston and colleagues noted that expression of human growth hormone via particle-mediated gene transfer resulted in the induction of antigen-specific antibody responses. 71 Since that time, several groups have demonstrated the successful immunization of laboratory animals against many viruses, bacteria, and parasites (reviewed by Donnelly et al, 18 ). More importantly, the efficacy of DNA immunization has been demonstrated in primates, 8, 15 and human clinical trials with DNA vaccinations against hepatitis B, herpes simplex, HIV, influenza, and malaria have shown promising results. 81 Recently, particlemediated DNA vaccination in mice has been successful in the immunization against other serious pathogens including hantavirus 27 , Ebola virus 77 , and rabies virus. 42 The burgeoning field of cancer vaccination has opened many new avenues of investigation for clinical investigators and molecular biologists. In general, the goal of cancer vaccination is to prime the host immune system against tumor cells. Many distinct approaches are in development. Some of these approaches include the introduction of foreign class I or class II MHC antigen genes to tumor cells, 3, 52 the use of vectors encoding tumor-associated antigens such as gp100, 
B. Gene Transfer with the Helios Gene Gun -The Process
A. Helios Gene Gun tyrosinase, carcinoembryonic antigen (CEA), 11, 30, 87 and the development of immunostimulatory techniques. 16 Human clinical trials are currently under way with cancer vaccines against prostate cancer, adenocarcinoma of the breast and colon, and several lymphomas.
81
Suicide Gene Therapy Many of the gene therapy applications currently in clinical trials involve the treatment or amelioration of various forms of cancers or infectious diseases. In fact, gene therapy has become a standard experimental approach for treating cancer patients that have failed conventional therapies. One of the most promising anti-tumor gene therapy techniques involves the concept of "suicide gene therapy." 23, 24 In this approach, a "suicide gene," such as herpes simplex virus thymidine kinase gene (HSV-TK), is introduced into tumor cells under the control of tumor-specific promoters. The use of tumor-specific promoters restricts expression of the transgene to tumor cells only. Tumor cells expressing the HSV-TK gene convert the prodrug, ganciclovir (GCV), by phosphorylation into a highly toxic form. This toxic metabolite disrupts DNA replication and results in the death of the cell. GCV by itself is virtually nontoxic to cells not expressing HSV-TK at therapeutic concentrations. GCV, therefore, is nontoxic to normal tissues. Although this technique has not been investigated extensively with particle-mediated delivery, many experiments using viral delivery and direct injection have been successful. Suicide gene therapy has been demonstrated to be effective in the treatment of neuroblastoma 14 and melanoma 78 in animal models, and many clinical trials using suicide genes in melanoma and other cancers are currently under way.
24, 33
Immunomodulation
Immunomodulation is closely related to the fields of cancer vaccination and suicide gene therapy. In all three approaches, the desired effect is the destruction of unwanted tumor cells, mediated by either the stimulated immune system and/or gene product itself. One such approach involves the stimulation of the immune response to weakly immunogenic tumors, achieved by transfection with various cytokines (e.g., granulocyte/ macrophage colony-stimulating factor (GM-CSF). 46 Theoretically, the immune response will be augmented against the transfected tumor cells at the vaccination site, as well as at distant non-transfected tumors. 30 Particle-mediated introduction of interferon α cDNA has been shown to produce local antitumor immunity in tumor establishment models. 72 IL-2, IL-6, interferon α, and interferon γ cDNA have also been shown to be effective in the reduction of tumor growth in mice. 70 More interestingly, gene gun delivery of IL-12 cDNA in murine models showed that local expression of IL-12 in epidermal cells near tumor cells resulted in regression of underlying tumors and inhibition of systemic metastasis, resulting in prolonged survival of test mice. 59 This study suggests that immune stimulation by gene gun techniques can result in local as well as systemic anti-cancer effects.
Genetic Pharmacology
A particularly promising application of gene therapy relates to genetic pharmacology. 25 With this approach, DNA encoding therapeutically beneficial genes is administered to tissues, and these gene products result in the pharmacological improvement of the patient. Current applications of genetic pharmacology being studied are the production of various clotting factors in hematologic disorders or use of erythropoetin-encoding DNA for enhanced red blood cell reproduction in patients with chronic anemias. 20, 36 Similarly, expression of various hormones, growth factors, etc., can modify pathological conditions. Methods of administration of such genes include, for example, intramuscular injections, introduction of the genes to the skin by gene gun delivery, or grafting of genetically modified keratinocytes into the skin. 39 Just as the route of administration of a drug (i.e., PO/IV/IM) may affect its therapeutic level, the mode of gene delivery may dramatically affect the therapeutic level of the transgene expression. For example, intramuscular injection of erythropoetin cDNA elicits a rise in hematocrit that persists for eight months. 82 However, the hematocrit can reach pathologic levels in the 75 to 90% range. In contrast, monthly gene gun applications of the erythropoetin cDNA to mouse skin resulted in a stable increase in hematocrit. With the gene gun, the level of erythrocyte production could be controlled by the adjustment of the dose and frequency of the transgene application. 82 Thus, the "gene gun" administration of plasmid DNA resulted in tighter regulation of secretion of the exogenous gene product.
The Gene Gun as a Research Tool: Promoter-Based Gene Expression
Promoter-based gene expression was initially developed in cancer research to restrict the expression of therapeutic genes to specific tumor cells. Since tumors often produce the same proteins as the original tissue of origin, the promoter sequences that control the expression of these proteins can be utilized to control the expression of the transgenes. For example, the α-fetoprotein promoter can be used to restrict expression to liver tumors, 28 the surfactant protein promoter to lung cancer cells, 68 and the tyrosinase promoter to melanoma cells. 26 Promoter-based gene expression can be applied to cutaneous gene therapy to restrict the expression of introduced genes also to specific cell layers. Since many cell layers in the skin produce specific proteins, promoter sequences from the corresponding genes can be incorporated into the vectors to restrict the transgene expression to those layers. Layer-specific expression has been demonstrated in transgenic mice using the keratin 14 (K14) 80 and keratin 5 (K5) promoters. 9 Using the gene gun, one can quickly identify the strength and specificity of different promoters in the skin. The use of particlemediated gene delivery (i.e., gene gun) to study promoter-based gene expression has only recently been developed. Cheng et al. compared various viral and cellular promoters in the epidermis and other tissue. Among ten promoters investigated, the CMV promoter was shown to be the strongest in the epidermis, followed by the mouse metallothionein gene promoter. 10 
A
Similarly, using the gene gun and promoter-based expression, Shiraishi et al. delivered DNA to the cornea, conjunctiva, and skin. Using keratin 12 promoter sequences, restriction of reporter gene expression to the cornea was achieved. 67 As an illustration of the applicability of the gene gun approach, we have bombarded mouse skin with a construct consisting of a LacZ reporter gene, encoding β-galactosidase driven by an involucrin promoter (Figure 4 ). Mice were sacrificed at 24, 48, and 158 hr. The LacZ expression was noted to have decreased by 48 hr and was undetectable by day 7. Although the construct, which was bound to the gold particles, was delivered to both the dermis and epidermis, gene expression was limited to the epidermis ( Figure 4B ). Therefore, a transgene regulated by an involucrin promoter was expressed only in the superficial epidermal layers, which coincides with the normal physiologic expression of involucrin (see Figure 4B ). 45 Of particular interest is the prospect of targeting epidermal stem cells by promoter-based techniques. The epidermis is a rapidly proliferating and differentiating tissue. Therefore, a dilemma in cutaneous gene therapy relates to the difficulty in maintaining gene expression due to the rapid epidermal turnover. Since keratinocyte stem cells are the progenitors of all other keratinocytes in the epidermis, gene delivery to these key cells remains an important long-term goal to maintain sustained gene expression. 5 Ultimately, if a unique promoter can be found to be specific for stem cells, such a promoter can be utilized for identification and enrichment of stem cell populations. Evidence that keratin 19 may be a marker for stem cells 50 has prompted investigation into the use of the keratin 19 promoter for stem cell identification.
Conclusions
As the field of gene therapy progresses, no one delivery system will likely be superior in all situations. Each delivery system is distinctive. For example, certain delivery systems allow for long-term expression (i.e., retroviruses), while others result in short-term expression only (i.e., gene gun). Also, in genetic vaccination, differences in the patterns of immunostimulation elicited by intramuscular and cutaneous gene gun delivery may lead to more effective vaccination by one modality than another based upon the specific application. Finally, certain delivery systems are more amenable to systemic delivery (i.e., viral), while others are effective in local delivery only.
The gene gun has proven to be useful in gene therapy research and has many potential clinical applications. Although the gene gun has limited applicability in "conventional gene therapy" (i.e., gene replacement), the prospects of using the gene gun in genetic vaccines, genetic pharmacology, and cancer therapy are particularly exciting. The gene gun's ability to deliver genes to a variety of cell types without viruses or toxic chemicals offers distinctive advantages over other delivery systems. Therefore, the gene gun will likely remain a standard gene delivery technique in future gene therapy applications.
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